Genmab A/S (OTCMKTS:GNMSF – Get Free Report) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 61,100 shares, a decline of 23.5% from the February 13th total of 79,900 shares. Based on an average trading volume of 300 shares, the short-interest ratio is currently 203.7 days. Approximately 0.1% of the company’s shares are short sold.
Genmab A/S Price Performance
GNMSF traded up $11.07 during midday trading on Monday, reaching $208.89. 427 shares of the company’s stock traded hands, compared to its average volume of 3,166. The firm has a fifty day moving average of $211.21 and a two-hundred day moving average of $222.86. The stock has a market capitalization of $13.80 billion, a price-to-earnings ratio of 11.92 and a beta of 1.08. Genmab A/S has a 52 week low of $186.61 and a 52 week high of $310.56.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $5.70 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- What is diluted earnings per share (Diluted EPS)?
- Super Micro’s International Presence Makes It a Winning Stock
- Election Stocks: How Elections Affect the Stock Market
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
- How to Use the MarketBeat Excel Dividend Calculator
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.